DOD has compounded drugs tested; What do sales of Gilead's hep C drugs portend?;

@FiercePharma: Remember, you can keep on voting in #FierceMadness Round 2 all through the weekend. Vote | Follow @FiercePharma

@EricPFierce: India's Micro Labs, whose Bangalore plant was banned by FDA, is recalling simvastatin made at Goa facility. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Another reason to vote in #FierceMadness: Once you do, you can see others' comments, which so far have proven to be my favorite thing ever. | Follow @CarlyHFierce

> The U.S. Department of Defense is having Express Scripts ($ESRX) screen all ingredients used in compounded medications to ensure that make sure they are all FDA approved. Story

> In typical fashion, a federal agency in India is blaming its IT department for the fact that it didn't follow procedures an apparently allowed drugmakers to collected more in incentives than they were entitled. Story

> There are differing estimates and differing analyses of what the sales of Gilead Sciences' ($GILD) hep C drugs will be and mean for the drugmaker. Report

Medical Device News

@FierceMedDev: Roche joins forces with Sigma-Aldrich to distribute biochemical reagents. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: I'm going to skip work and fill out my #FierceMadness bracket at the bar! Check it out | Follow @VarunSaxena2

@EmilyWFierce: Merck KGaA to tap Oschmann as new CEO, sources report. Article | Follow @EmilyWFierce

> Philips to help fund HealthTech refocus with 2016 lighting biz IPO. Story

> GE tech hub develops innovative handheld probe for bedsore monitoring. Article

Biotech News

@FierceBiotech: ICYMI: Retrophin bags rare disease approval, FDA voucher in $75M deal. Article | Follow @FierceBiotech

@JohnCFierce: The interesting headline on the top revenue report, $LLY gets nudged out of top 10 by a booming $GILD--$LLY now #14. FiercePharma feature | Follow @JohnCFierce

@DamianFierce: Here are some particularly tight #FierceMadness matchups in Round 1. Cast your votes here | Follow @DamianFierce

> Amgen fails to block Novartis' Neupogen biosimilar. Item

> Lilly inks a $456M oncology deal with China's Innovent. Article

> Biogen's Alzheimer's drug impresses in early study with Phase III on the way. Report

And Finally... A pair of philanthropic organizations has launched a global fund to help low- and middle-income countries fight legal challenges to their anti-smoking laws. More (sub. req.)

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.